J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia
J&J is adding a $230 million bonus deal to its $30 billion buyout of Actelion.
The pharma giant just snagged commercialization rights on aprocitentan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
